Mayer Brown announced today that it represented Adaptimmune Therapeutics, a Nasdaq-listed cancer immunotherapy company, on a $62 million public equity offering. The offering was led by Citigroup, Cowen and Company and Leerink Partners and was done as a confidentially marketed public offering. Following that offering, Adaptimmune did a registered direct offering and raised an additional $42 million.

The Mayer Brown team was led by New York-based Corporate & Securities partner David Bakst and included lawyers from the firm’s Corporate & Securities, Employment & Benefits, Intellectual Property, Litigation & Dispute Resolution and Tax Transactions & Consulting practices in Chicago, London, New York, São Paulo and Washington DC.